Form 4: IRADIMED Director Boosts Stake with RSU Conversion

IRADIMED Director James B. Hawkins acquired 905 shares of common stock through the vesting and conversion of restricted stock units, increasing his beneficial ownership.

Summary

• James B. Hawkins, a Director of IRADIMED CORP (IRMD), acquired 905 shares of common stock.
• The acquisition occurred on December 11, 2025, through the conversion of Restricted Stock Units (RSUs).
• These RSUs were granted on December 11, 2024, under Iradimed Corporation's 2023 Equity Incentive Plan.
• The RSUs vest in two equal annual installments, with the first installment vesting on December 11, 2025.
• Following this transaction, Mr. Hawkins beneficially owns 29,647 shares of IRADIMED common stock.
• Restricted stock units convert into common stock on a one-for-one basis.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director through RSU conversion is generally a positive signal, indicating continued alignment of interests between management and shareholders and confidence in the company's performance.

Positives

• Increased insider ownership by a Director, James B. Hawkins, which can signal confidence in the company's future prospects.
• The acquisition of 905 shares adds to the Director's total beneficial ownership, now standing at 29,647 shares.

Future Outlook

The remaining restricted stock units will vest in a future annual installment, further increasing the reporting person's beneficial ownership upon conversion.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively, signaling management's confidence and aligning their interests with long-term shareholder value.
• Employees: The equity incentive plan provides a mechanism for employee and director compensation, potentially motivating performance.

Next Steps

• Future vesting of the remaining restricted stock units in subsequent annual installments.

Key Dates

Recommendation

The acquisition of shares by a director through RSU conversion is a routine, pre-scheduled event under an equity incentive plan. While it indicates continued insider confidence and alignment, it does not represent a discretionary open-market purchase that would typically warrant a 'buy' recommendation based solely on this filing. It reinforces a 'hold' position for existing investors and provides a positive data point for potential investors.

Keywords

IRADIMED CORP, IRMD, James B. Hawkins, Director, Insider Transaction, Form 4, Restricted Stock Units, RSU Conversion, Equity Incentive Plan, Stock Acquisition